Other
Explore all topics, guides, and frameworks related to Other.
Articles in this section
87- Venlafaxine: Discovery, Development, Safety and Pharmacovigilance An evidence-based account of venlafaxine's serotonin–noradrenaline pharmacology, depression and anxiety evidence, regional labels, dose-related blood-pressure risk, withdrawal syndromes, interactions and pharmacovigilance. Read Article →
- Tramadol: Discovery, Development, Safety and Pharmacovigilance A lifecycle review of tramadol from GrĂĽnenthal development to current pharmacovigilance, integrating analgesic evidence, metabolism, respiratory depression, seizures, serotonin toxicity, dependence and regional label interpretation. Read Article →
- Venetoclax: Discovery, Development, Safety and Pharmacovigilance A lifecycle review of venetoclax from selective BCL-2 discovery to modern combination regimens and their pharmacovigilance. Read Article →
- Ruxolitinib: Discovery, Development, Safety and Pharmacovigilance An evidence-based lifecycle account of ruxolitinib, its pivotal trials, Incyte–Novartis development, evolving formulations and paediatric indications, myelosuppression, infections, treatment interruption and US/EU listedness. Read Article →
- Pomalidomide: Discovery, Development, Safety and Pharmacovigilance A lifecycle reference on pomalidomide in myeloma and US Kaposi sarcoma, including trials, pregnancy prevention, cytopenias, thrombosis, infection, product information and case-to-signal assessment. Read Article →
- Potassium Chloride: Development, Replacement Therapy, Safety and Pharmacovigilance A lifecycle and product-safety review of potassium chloride, distinguishing solid oral, liquid and intravenous presentations and the limits of public-label listedness. Read Article →
- Prednisone: Discovery, Development, Safety and Pharmacovigilance A source-based history and safety reference for prednisone, distinguishing the prodrug from prednisolone, short courses from chronic exposure, formulation-specific authorisation and adverse-reaction listedness, and patient-level monitoring from regulatory case assessment. Read Article →
- Olaparib: Discovery, Development, Safety and Pharmacovigilance Olaparib's development from DNA-repair biology to biomarker-selected oncology, with attention to trial interpretation, myeloid malignancies, pneumonitis, thromboembolism, hepatotoxicity and US/EU product information. Read Article →
- Lenalidomide: Discovery, Development, Safety and Pharmacovigilance A lifecycle and pharmacovigilance reference for lenalidomide capsules, integrating discovery, cereblon biology, pivotal haematology trials, US and EU product information, pregnancy-risk controls and practical case assessment. Read Article →
- Ibuprofen: Discovery, Development, Safety and Pharmacovigilance Explains ibuprofen's invention and commercial evolution, cyclooxygenase pharmacology, dose- and context-dependent clinical evidence, current US/UK prescription-label listedness and practical pharmacovigilance across prescription and nonprescription exposure. Read Article →
- Hydroxyzine: Discovery, Development, Safety and Pharmacovigilance Lifecycle review of hydroxyzine from its early sedating-antihistamine use through European cardiac-risk restrictions, product-specific adverse reactions and case-to-signal evaluation. Read Article →
- Ibrutinib: Discovery, Development, Safety and Pharmacovigilance An evidence-based lifecycle and drug-safety review of ibrutinib, including FDA and EMA product information, clinical evidence, medication interactions, and case-to-signal assessment. Read Article →
- Formoterol: Discovery, Development, Safety and Pharmacovigilance Traces formoterol from Yamanouchi's early patents through Foradil, Oxis and nebulised/combination formulations; explains beta2 signalling, inhaler and indication boundaries, LABA asthma safety, systemic effects and product-specific pharmacovigilance. Read Article →
- Famotidine: Discovery, Development, Safety and Pharmacovigilance A product-lifecycle review of famotidine, its discovery and clinical development, comparative acid suppression, renal accumulation, CNS and cardiac reactions, formulation-specific labels and practical pharmacovigilance. Read Article →
- Carvedilol: Discovery, Development, Safety and Pharmacovigilance A lifecycle review of carvedilol as an alpha- and beta-adrenoceptor blocker, its pivotal clinical evidence, titration risks, interactions, and US/UK product-specific safety assessment. Read Article →
- Buspirone: Discovery, Development, Safety and Pharmacovigilance A product-specific lifecycle and safety review, including US and UK regulatory labels and case-to-signal assessment. Read Article →
- Budesonide: Discovery, Development, Safety and Pharmacovigilance A scientific and regulatory account of budesonide, from Swedish corticosteroid chemistry to contemporary airway and gastrointestinal therapies, explaining local delivery, systemic steroid risk, formulation-specific labelling and safety surveillance. Read Article →
- Zanubrutinib: Discovery, Development, Safety and Pharmacovigilance Explains zanubrutinib's invention, trial evidence, approvals, safety profile, current US and EU listedness, formulation differences and practical oncology pharmacovigilance. Read Article →
- Vilanterol: Discovery, Development, Safety and Pharmacovigilance An ingredient-centred account of vilanterol from medicinal chemistry and early dose finding to dual and triple Ellipta inhalers, clinical evidence, beta-agonist risks, device errors and product-specific US–EU listedness. Read Article →
- Umeclidinium: Discovery, Development, Safety and Pharmacovigilance A formulation-specific, evidence-based history of umeclidinium bromide: discovery and pharmacology, once-daily Ellipta development, pivotal and combination trials, 2014 authorisations, the 2024 European post-authorisation cardiovascular study, current US and European safety information, device errors and case assessment. Read Article →
- Tamsulosin: Discovery, Development, Safety and Pharmacovigilance A source-based clinical and pharmacovigilance history of tamsulosin: discovery and controlled release, trial evidence and limits, commercial evolution, regional prescribing information, preventable ophthalmic and orthostatic risks, listedness and practical case assessment. Read Article →
- Trazodone: Discovery, Development, Safety and Pharmacovigilance A product-specific review of trazodone's serotonin pharmacology, clinical trials, US and UK regulatory history, safety warnings, medication errors and signal assessment. Read Article →
- Simvastatin: Discovery, Development, Safety and Pharmacovigilance A lifecycle review of the HMG-CoA reductase inhibitor simvastatin, covering its semisynthetic origin, cardiovascular trials, dose-related myopathy, pharmacogenetics, pregnancy labelling and practical pharmacovigilance. Read Article →
- Ribociclib: Discovery, Development, Safety and Pharmacovigilance How ribociclib moved from cell-cycle targeting into advanced and early breast cancer, what its pivotal trials established, and why QT prolongation, hepatotoxicity, neutropenia and pulmonary or cutaneous reactions require structured safety oversight. Read Article →
- Pantoprazole: Discovery, Development, Safety and Pharmacovigilance An evidence-based lifecycle review of pantoprazole from acid-suppression pharmacology through clinical development, regulatory indications, recognised adverse reactions and practical pharmacovigilance. Read Article →
- Paliperidone: Discovery, Development, Safety and Pharmacovigilance A source-based lifecycle review of paliperidone covering its chemical origin, controlled-release and injectable formulation strategy, schizophrenia and schizoaffective evidence, adverse reactions, interaction and renal risks, regional labelling and safety-system governance. Read Article →
- Palbociclib: Discovery, Development, Safety and Pharmacovigilance An evidence-based lifecycle review of palbociclib, distinguishing progression-free survival from overall survival, negative adjuvant trials, 2026 US indication expansions, EU label scope and operational drug-safety assessment. Read Article →
- Nintedanib: Discovery, Development, Safety and Pharmacovigilance An evidence-based lifecycle review of nintedanib from oncology-oriented kinase research to treatment of progressive fibrosing interstitial lung diseases, with a focus on product-specific safety surveillance. Read Article →
- Montelukast: Discovery, Development, Safety and Pharmacovigilance An evidence-based review of cysteinyl-leukotriene antagonism, pivotal asthma and rhinitis trials, the 2020 FDA boxed warning, 2024 MHRA action, evolving observational evidence and product-specific safety assessment. Read Article →
- Hydrochlorothiazide: Discovery, Development, Safety and Pharmacovigilance A clinically and regulatorily grounded account of hydrochlorothiazide from the thiazide discovery era to contemporary prescribing, cumulative-exposure safety signals, product labelling and operational pharmacovigilance. Read Article →
- Fluticasone Propionate: Discovery, Development, Safety and Pharmacovigilance A formulation-specific lifecycle of fluticasone propionate: medicinal chemistry, asthma and rhinitis studies, inhaler and nasal-delivery innovation, evolving regulatory and commercial access, adverse reactions and practical pharmacovigilance. Fluticasone furoate is treated as a distinct drug substance. Read Article →
- Fluticasone Furoate: Discovery, Development, Safety and Pharmacovigilance An evidence-led lifecycle of fluticasone furoate from GSK medicinal chemistry and allergic-rhinitis trials through asthma and COPD inhalers, including negative trial results, device-related errors, US–EU nasal listedness, systemic corticosteroid risks and EU pharmacovigilance assessment. Read Article →
- Fluoxetine: Discovery, Development, Safety and Pharmacovigilance From Lilly's serotonin-uptake research and the 1987 US approval to current product-specific labelling, this review examines fluoxetine's evidence, limitations, risks and pharmacovigilance. Read Article →
- Efmoroctocog Alfa: Discovery, Development, Safety and Pharmacovigilance A source-grounded review of efmoroctocog alfa, the extended-half-life recombinant factor VIII–Fc fusion protein, from molecular design and clinical trials through authorisation and long-term safety surveillance. Read Article →
- Bupropion: Discovery, Development, Safety and Pharmacovigilance Bupropion's chemistry, early clinical programme, dose-dependent seizure history, formulations, pivotal trials, regulatory differences, drug interactions, postmarketing signals and case-assessment practice. Read Article →
- Amoxicillin: Discovery, Development, Safety and Pharmacovigilance Amoxicillin emerged from the 6-aminopenicillanic-acid programme that transformed penicillin into a family of semisynthetic antibiotics. This article follows its discovery and early comparative pharmacology, clinical and commercial evolution, regional regulatory information, antibacterial resistance, adverse-reaction profile and the pharmacovigilance decisions needed to distinguish drug reactions from infection, formulation and concomitant-treatment effects. Read Article →
- Abemaciclib: Discovery, Development, Safety and Pharmacovigilance Evidence-led review of abemaciclib's discovery, clinical trials, US and EU regulatory evolution, gastrointestinal and haematological toxicity, pneumonitis, thrombosis, liver injury, transporter-mediated creatinine changes and pharmacovigilance. Read Article →
- Antidepressant Safety in 2026: Persistent Sexual Dysfunction, Suicidality and the MHRA's New Risk-Minimisation Measures In October 2026 the MHRA strengthened how antidepressant risks are communicated in the UK after a multi-year review involving patients, families, experts and the Commission on Human Medicines. This article explains the regulatory history, the evidence and uncertainty around suicidal thoughts and behaviours and persistent sexual dysfunction, the new risk-minimisation measures, and what the changes mean for pharmacovigilance systems, marketing authorisation holders and effectiveness evaluation. Read Article →
- Penpulimab: Development, PD-1 Biology, Clinical Evidence, Safety and Pharmacovigilance Penpulimab is an Fc-engineered IgG1 anti-PD-1 monoclonal antibody developed as AK105. This article follows its development from Akeso's antibody programme and the Akeso–Chia Tai Tianqing collaboration through its first 2021 Chinese approval, subsequent indication expansion and 2025 US approval, then connects PD-1 biology and product-specific clinical evidence to immune-mediated toxicity, combination-regimen attribution, traceability, signal assessment and lifecycle pharmacovigilance. Read Article →
- Zenocutuzumab: Classification, Mechanism, Evidence and Pharmacovigilance Explains zenocutuzumab’s HER2/HER3 bispecific mechanism, tumour-specific U.S. regulatory history, eNRGy evidence, labelled safety concerns and practical pharmacovigilance. Read Article →
- Xeligekimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance Covers xeligekimab’s IL-17A blockade, China NMPA status, phase 3 psoriasis evidence, safety interpretation and pharmacovigilance considerations. Read Article →
- Vunakizumab: Classification, Mechanism, Evidence and Pharmacovigilance Explains vunakizumab’s pathway, China indication, phase 3 evidence, safety interpretation and pharmacovigilance priorities. Read Article →
- Tisotumab Vedotin: Classification, Mechanism, Safety and Pharmacovigilance Tisotumab vedotin is a tissue-factor-directed antibody-drug conjugate carrying monomethyl auristatin E. Its pharmacovigilance profile is distinguished by ocular toxicity and required eye-risk controls, alongside haemorrhage, peripheral neuropathy, pulmonary toxicity and treatment-administration issues. Read Article →
- Telisotuzumab Vedotin: Classification, Mechanism, Clinical Evidence and Pharmacovigilance Explains the antibody–drug conjugate design, c-Met biomarker selection, FDA accelerated approval, clinical evidence, payload-related safety signals and pharmacovigilance priorities. Read Article →
- Stapokibart: Classification, Mechanism, Clinical Evidence and Pharmacovigilance Explains stapokibart’s shared IL-4/IL-13 pathway blockade, China NMPA status, phase 3 evidence, safety interpretation and pharmacovigilance considerations. Read Article →
- Sotrovimab: Classification, Mechanism, EU Authorisation History and Pharmacovigilance Sotrovimab is a human IgG1 monoclonal antibody directed against the SARS-CoV-2 spike protein. Its EU marketing authorisation was withdrawn in February 2026 at the holder's request for commercial reasons. This article explains the historical indication, mechanism, product-specific safety information, variant context and practical requirements for assessing cases arising during its authorised use. Read Article →
- Siltartoxatug: Classification, Mechanism, Evidence and Pharmacovigilance Explains siltartoxatug’s passive-immunisation role, target, China authorisation, phase 3 evidence, safety limits and pharmacovigilance priorities. Read Article →
- Serplulimab: Classification, Mechanism, Evidence and Pharmacovigilance Explains serplulimab’s checkpoint mechanism, current EMA scope, pivotal evidence, immune-mediated risks and practical safety assessment. Read Article →
- Sibeprenlimab: Classification, Mechanism and Pharmacovigilance Sibeprenlimab is a humanised IgG2 monoclonal antibody that blocks APRIL signalling. This article explains the relationship between APRIL and pathogenic IgA1 in primary IgA nephropathy, the U.S. accelerated indication, interim and later VISIONARY trial evidence, infection and immunoglobulin considerations, and practical pharmacovigilance assessment. Read Article →
- Regdanvimab: Classification, Mechanism, EU Authorisation History and Pharmacovigilance Regdanvimab is a recombinant human IgG1 monoclonal antibody that binds the SARS-CoV-2 spike receptor-binding domain. Its EU marketing authorisation for Regkirona was withdrawn in April 2025 at the holder's request for commercial reasons. This article reviews the historic indication, variant-sensitive mechanism, labelled safety topics and the exposure, disease-course and product information needed for reliable pharmacovigilance. Read Article →
- Recaticimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance Covers recaticimab’s PCSK9–LDL receptor mechanism, China NMPA status, phase 3 evidence, safety interpretation and practical pharmacovigilance considerations. Read Article →
- Pozelimab: Classification, Mechanism and Pharmacovigilance Pozelimab is a fully human monoclonal antibody that binds complement component C5. This article explains its U.S.-authorised use in CD55-deficient protein-losing enteropathy (CHAPLE disease), its clinical evidence, infection precautions and pharmacovigilance context. Read Article →
- Pivekimab Sunirine: Classification, Mechanism, Evidence and Pharmacovigilance Explains pivekimab sunirine’s CD123-targeted conjugate design, 2026 U.S. authorisation, CADENZA evidence, hepatic veno-occlusive disease risk and practical pharmacovigilance in BPDCN. Read Article →
- Pharmacovigilance Reconciliation: What Should Be Reconciled, With Whom and How Often? Reconciliation helps show that safety information moved through the pharmacovigilance system as intended. This article explains how to decide what to reconcile across medical information, complaints, affiliates, vendors, studies, literature, digital channels and other sources; how to define populations and matching rules; how to set a justified frequency; and how to investigate and govern exceptions. Read Article →
- Pharmacovigilance Record Retention and Archiving This article explains how to manage pharmacovigilance records across their lifecycle. It distinguishes the EU legal retention periods for human-medicines PV records from other applicable requirements, then shows how to classify records, preserve provenance and audit trails, maintain access through system and vendor changes, test retrieval, manage holds and authorise secure destruction. Read Article →
- Business Continuity and Disaster Recovery in Pharmacovigilance This article explains how to prepare a risk-based pharmacovigilance continuity capability. It distinguishes business continuity from disaster recovery, translates PV obligations into recovery priorities, defines operational recovery objectives, and sets out incident activation, temporary workarounds, data restoration, backlog reconciliation, testing, QPPV oversight and inspection evidence. Read Article →
- Pemivibart: Classification, Mechanism and Pharmacovigilance Pemivibart is a monoclonal antibody that binds the SARS-CoV-2 spike receptor-binding domain. This article explains its emergency-authorised use for pre-exposure prophylaxis in selected immunocompromised people, the variant-dependent limits of activity, the immunobridging evidence, anaphylaxis risk and practical pharmacovigilance case assessment. Read Article →
- Ongericimab: Classification, Mechanism, Evidence and Pharmacovigilance Explains ongericimab’s mechanism, China indication, phase 3 lipid endpoint, safety interpretation and pharmacovigilance considerations. Read Article →
- Olaratumab: Classification, PDGFRα Mechanism, EU History and Pharmacovigilance Olaratumab is a human IgG1 monoclonal antibody directed against platelet-derived growth factor receptor alpha (PDGFRα). Lartruvo received a conditional EU marketing authorisation in 2016 with doxorubicin for advanced soft tissue sarcoma; the authorisation was later revoked after the confirmatory ANNOUNCE study did not show improved survival. This article explains the mechanism, historical evidence, safety context and pharmacovigilance lessons. Read Article →
- Nonacog Alfa: Classification, Mechanism, Safety and Pharmacovigilance Nonacog alfa is a recombinant coagulation factor IX replacement therapy for haemophilia B. Its pharmacovigilance profile centres on treatment response and recovery, inhibitor formation, hypersensitivity including reactions associated with inhibitors, thrombosis, surgical use, home administration and biological-product traceability. Read Article →
- Obiltoxaximab: Classification, Mechanism, Regulatory Evidence and Pharmacovigilance Explains obiltoxaximab’s toxin-neutralising mechanism, U.S. Animal Rule approval, human safety evidence, EU exceptional-circumstances authorisation and withdrawal, and emergency-use pharmacovigilance. Read Article →
- Nimotuzumab: Classification, Mechanism and Pharmacovigilance Nimotuzumab is a humanised IgG1 monoclonal antibody that binds epidermal growth factor receptor (EGFR). This article explains its mechanism, the limits of cross-jurisdictional product information, the 2008 withdrawal of its EU marketing application, clinical evidence and safety-reporting considerations. Read Article →
- Necitumumab: Classification, EGFR Mechanism, EU History and Pharmacovigilance Necitumumab is a human IgG1 monoclonal antibody that binds EGFR. The Portrazza EU marketing authorisation expired on 18 February 2021 after the holder did not apply for renewal. This article covers the historical combination indication, cardiovascular, thromboembolic, dermatological and electrolyte risks, and the product-level data needed to assess cases from its authorised period. Read Article →
- Narsoplimab: Classification, Mechanism and Pharmacovigilance Narsoplimab is a monoclonal antibody that inhibits MASP-2, an enzyme in the lectin pathway of complement. This article explains its U.S.-authorised use in haematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA), the evidence and safety context, pharmacovigilance assessment, and the distinct European review outcome. Read Article →
- Moroctocog Alfa: Classification, Mechanism, Safety and Pharmacovigilance Moroctocog alfa is a B-domain-deleted recombinant factor VIII replacement therapy for haemophilia A. Its pharmacovigilance profile centres on inhibitor development and unexpected lack of efficacy, laboratory recovery and assay interpretation, hypersensitivity, thrombosis, surgery, home administration and biological-product traceability. Read Article →
- MHRA Beyond ADMET: AI for Medicines Safety and the Regulatory Sandbox The MHRA's Beyond ADMET programme is exploring how AI-based methods could contribute to medicines-safety evaluation by integrating preclinical, clinical and real-world data. This article explains what the regulatory sandbox is, what it is not, the evidence questions it is intended to address, and how pharmacovigilance professionals should interpret AI-derived safety evidence. Read Article →
- Medical Information and Pharmacovigilance: AE Intake, Escalation and Reconciliation Medical Information teams answer product questions, but a question can also disclose a suspected adverse reaction. This article explains how to design the intake, escalation, follow-up, reconciliation, training and oversight controls that preserve the reporter's account and connect medical enquiries to the pharmacovigilance system. Read Article →
- Margetuximab: Classification, Mechanism and Pharmacovigilance Margetuximab is an Fc-engineered monoclonal antibody targeting HER2. This article explains its U.S.-authorised use with chemotherapy in previously treated metastatic HER2-positive breast cancer, the clinical evidence, labelled risks and product-specific pharmacovigilance. Read Article →
- Ivonescimab: Classification, Mechanism, Evidence and Pharmacovigilance Explains ivonescimab’s dual-target design, China NMPA indication, HARMONi-A evidence, safety interpretation and pharmacovigilance priorities. Read Article →
- Ibritumomab Tiuxetan: Classification, Radioimmunotherapy, EU History and Pharmacovigilance Ibritumomab tiuxetan is a murine anti-CD20 antibody conjugated to the tiuxetan chelator and used in a radiopharmaceutical kit with yttrium-90 or indium-111. Zevalin's EU marketing authorisation lapsed on 4 January 2024 after the product had not been marketed in the EU since May 2020. This article explains the radioimmunotherapy workflow, historical indication, safety profile and product-specific traceability needs for pharmacovigilance. Read Article →
- Garetosmab: Classification, Mechanism, Evidence and Pharmacovigilance Explains garetosmab’s activin A mechanism, 2026 U.S. authorisation, heterotopic-ossification and flare evidence, safety profile and pharmacovigilance priorities in fibrodysplasia ossificans progressiva. Read Article →
- FDA Adverse Event Monitoring System (AEMS): Dashboard Use and Pharmacovigilance Practice A practical guide to the FDA Adverse Event Monitoring System (AEMS): what the platform and public dashboard contain, how AEMS relates to legacy FAERS data and electronic ICSR submissions, what dashboard queries can and cannot show, and how to document a defensible signal review. Read Article →
- Enfortumab Vedotin: Classification, Mechanism, Safety and Pharmacovigilance Enfortumab vedotin is a Nectin-4-directed antibody-drug conjugate carrying the microtubule-disrupting payload monomethyl auristatin E. Its pharmacovigilance profile is shaped by both target biology and payload toxicity, with particular attention to severe cutaneous reactions, hyperglycaemia, peripheral neuropathy, ocular events, pneumonitis and combination-regimen attribution. Read Article →
- Emapalumab: Classification, Mechanism and Pharmacovigilance Emapalumab is a monoclonal antibody that neutralises interferon gamma (IFNÎł). This article connects its cytokine target to primary haemophagocytic lymphohistiocytosis (HLH) and Still’s disease-associated HLH/macrophage activation syndrome (MAS), reviews clinical evidence and labelled risks, and explains why the FDA and EMA reached different regulatory outcomes. Read Article →
- Efalizumab: Mechanism, EU Withdrawal and Pharmacovigilance Efalizumab is a humanised monoclonal antibody against CD11a, part of the lymphocyte function-associated antigen 1 (LFA-1) complex. Raptiva was authorised in the EU for selected adults with moderate-to-severe plaque psoriasis and withdrawn in June 2009 after EMA concluded that modest benefit no longer outweighed serious risks, including progressive multifocal leukoencephalopathy (PML). This article reviews the safety signal, exposure context and pharmacovigilance lessons. Read Article →
- Daclizumab Beta: Mechanism, EU Withdrawal and Pharmacovigilance Daclizumab beta is a humanised monoclonal antibody directed against the IL-2 receptor alpha chain (CD25). Its EU marketing authorisation for relapsing multiple sclerosis was withdrawn in March 2018 after reports of serious inflammatory brain disorders and evidence of serious, potentially fatal immune reactions affecting the brain, liver and other organs. This article covers the label history, post-treatment follow-up and case assessment. Read Article →
- Cosibelimab: Classification, Mechanism and Pharmacovigilance Cosibelimab is a human IgG1 antibody that blocks PD-L1. This article explains its target biology, U.S.-labelled use in advanced cutaneous squamous-cell carcinoma, the open-label evidence supporting approval, immune-mediated safety risks and practical pharmacovigilance case assessment. Read Article →
- Clesrovimab: Classification, Mechanism and Pharmacovigilance Clesrovimab is a long-acting monoclonal antibody that binds RSV fusion protein and provides passive protection during an infant’s first RSV season. This article explains its target, U.S. and EU indications, pivotal evidence, safety and immunogenicity findings, and the information needed to interpret breakthrough RSV or suspected adverse events. Read Article →
- CIOMS Working Group XIV: Artificial Intelligence in Pharmacovigilance — Guiding Principles and Practical Implementation The CIOMS Working Group XIV report provides a principles-based framework for responsible artificial intelligence in pharmacovigilance. This article explains the seven principles, their relationship to the EU regulatory environment, and how a PV organisation can translate them into risk assessment, validation, oversight, documentation and governance. Read Article →
- Catumaxomab: Classification, Mechanism, Authorisation History and Pharmacovigilance Catumaxomab is a rat–mouse hybrid trifunctional antibody that links EpCAM-positive tumour cells, CD3-positive T cells and FcÎł-receptor-bearing accessory cells. This article explains the transition from the former Removab authorisation to the current Korjuny authorisation, the step-up intraperitoneal regimen, inflammatory and hepatic risks, and the product-specific case information needed for reliable pharmacovigilance. Read Article →
- Brentuximab Vedotin: Classification, Mechanism, Safety and Pharmacovigilance Brentuximab vedotin is a CD30-directed antibody-drug conjugate carrying monomethyl auristatin E. Its pharmacovigilance profile is shaped by cumulative peripheral neuropathy, myelosuppression and infection, rare neurological and organ toxicities, and the changing attribution problem created by combination therapy. Read Article →
- Bezlotoxumab: Mechanism, EU Use and Pharmacovigilance Bezlotoxumab is a human IgG1 antibody that binds Clostridioides difficile toxin B. It is used with antibacterial treatment to reduce recurrence risk in selected patients, not to treat the active infection by itself. This article explains the product's role, EU indication, infusion and heart-failure safety context, and case-level pharmacovigilance priorities. Read Article →
- Besilesomab: Diagnostic Antibody, Radiopharmaceutical Use and Pharmacovigilance Besilesomab is a murine monoclonal antibody against NCA-95 used as a technetium-99m-labelled diagnostic radiopharmaceutical. Scintimun remains EU-authorised for imaging suspected peripheral-bone osteomyelitis in adults, in conjunction with other imaging modalities. This article explains diagnostic-use boundaries, hypersensitivity and human anti-mouse antibody considerations, radiopharmacy records and the case information needed for pharmacovigilance. Read Article →
- Axatilimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance Explains axatilimab’s antibody class, CSF-1R and macrophage biology, U.S. authorisation, AGAVE-201 evidence, safety profile, pharmacovigilance priorities and regulatory boundaries. Read Article →
- Avacopan: Drug-Induced Liver Injury and Vanishing Bile Duct Syndrome A product lifecycle and pharmacovigilance review of avacopan (Tavneos), focusing on how pre-authorisation hepatotoxicity concerns developed into post-marketing reports of serious and fatal drug-induced liver injury and biopsy-confirmed vanishing bile duct syndrome. Includes case-assessment and signal-management approaches and the distinct 2026 regulatory actions in the United States, European Union and United Kingdom. Read Article →
- Apitegromab: Classification, Mechanism, Evidence and Pharmacovigilance Explains apitegromab’s muscle-directed mechanism, 2026 U.S. authorisation, SAPPHIRE evidence, fracture signal and practical pharmacovigilance considerations in spinal muscular atrophy. Read Article →
- Ansuvimab: Classification, Mechanism and Pharmacovigilance Ansuvimab is a human monoclonal antibody that binds Zaire ebolavirus glycoprotein and prevents viral entry. This article explains its U.S. indication, the evidence from the PALM outbreak trial, infusion-related safety and the challenges of adverse-event assessment during Ebola disease. Read Article →